Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | https://onlinelibrary.wiley.com/doi/10.1002/psc.70070 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Antiproliferative Activity of the New Analogues of Acridine/Acridone With Oligopeptide Derivatives and Molecular Docking With EGFR and Src Kinase Monika Gensicka‐Kowalewska Krystyna Dzierzbicka Maria Skrzypkowska Mateusz Daśko Piotr Trzonkowski Journal of Peptide Science ABSTRACT The aim of our work was to analyze new functionalized analogues of 1‐nitroacridine/4‐methyl‐1‐nitroacridine and 4‐nitroacridone connected to tuftsin/retro‐tuftsin derivatives as a potential anticancer therapeutics. Using the MTT assay, we have evaluated the cytotoxic activity of synthesized analogues against the Jurkat cell line and healthy donor–isolated peripheral blood mononuclear cells (PBMCs). Jurkat cells were susceptible to several of the acridine derivatives, whereas PBMCs were sensitive to two compounds only. 4‐Methyl‐1‐nitro‐acridine analogue, classified as compound 28 , has exhibited the greatest anticancer potential with 4‐fold higher cytotoxicity toward Jurkat cells and 12‐fold lower cytotoxicity against PBMCs when compared with control therapeutics. Subsequent molecular docking analysis suggested that binding to epidermal growth factor receptor (EGFR) and proto‐oncogene tyrosine‐protein kinase Src molecules could be, at least partially, responsible for observed biological effects of created acridine/acridone analogues. 10.1002/psc.70070 http://onlinelibrary.wiley.com/termsAndConditions#vor